Response to treatment in minor and major depression: Results of a double-blind comparative study with paroxetine and maprotiline

Journal of Affective Disorders

Volumn 45, Issue 3, 1997, Pages 167-178

  Szegedi, A ^a   Wetzel, H ^a   Angersbach, D ^b   Philipp, M ^a   Benkert, O ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b SmithKline Beecham Pharma GmbH   (Germany)

Author keywords

Antidepressant pharmocotherapy; Maprotiline; Minor depression; Paroxetine

Indexed keywords

MAPROTILINE; PAROXETINE;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTIGO; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MAPROTILINE; MIDDLE AGED; PAROXETINE; PERSONALITY INVENTORY; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; XEROSTOMIA;

EID: 0030855990     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(97)00072-4     Document Type: Article

References (22)

1. Bech P. Acute therapy of depression. J. Clin. Psychiatry. 54(Suppl):1993;18-28.
2. Broadhead W.E., Blazer D.G., George L.K., Tse C.K. Depression, disability days, and days lost from work in a prospective epidemiology survey. JAMA. 264(19):1990;2524-2528.
3. Claghorn J.L., Feighner J.P. A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression. J. Clin. Psychopharmacol. 13(suppl. 2):1993;28-33.
4. Dechant K.L., Clissold S.P. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 41(suppl. 2):1991;225-253.
5. Duboff E. Long-term treatment of major depressive disorder with paroxetine. J. Clin. Psychopharmacol. 13(6, Supp 2):1993;28S-33S.
6. Dunbar G.C., Fuell D.L. The anti-anxiety and anti-agitation effects of paroxetine in depressed patients. Int. Clin. Psychopharmacol. 6(suppl. 4):1992;81-90.
7. Dunlop S.R., Dornseif B.E., Wernicke J.F., Potvin J.H. Pattern Analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacol. Bull. 26(2):1990;173-180.
8. Elkin I., Shea T., Watkins J.T., Imber S.D., Sotsky S.M., Collins J.F., Glass D.R., Pilkonis P.A., Leber W.R., Docherty J.P., Fiester S.J., Parloff M.B. National Institute of Mental Health Treatment of Depression Collaborative Research Program-General Effectiveness of Treatments. Arch. Gen. Psychiatry. 46:1989;971-982.
9. Horwath E., Johnson J., Klerman G.L., Weissman M.M. Depressive symptoms as relative and attributable risk factors for first onset major depression. Arch. Gen. Psychiatry. 49:1992;817-823.
10. Jaffe A., Froom J., Galambos N. Minor depression and functional impairment. Arch. Fam. Med. 3(12):1994;1081-1086.
11. Judd L.L., Rapaport M.H., Paulus M.P., Brown J.L. Subsyndromal symptomatic depression: a new mood disorder? J. Clin. Psychiatry. 55 Suppl:1994;18-28.
12. Keller M.B., Lavori P.W., Mueller I., Endicott J., Coryell W., Hirschfeld R.M., Shea T. Time to recovery, chronicity and levels of psychgopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch. Gen. Psychiatry. 49(10):1992;809-816.
13. Lapierre Y.D. Pharmacological therapy of dysthymia. Acta Psychiatr. Scand. Suppl 383:1994;42-48.
14. Nemeroff C.B. Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. J. Clin. Psychopharmacol. 13(suppl. 2):1993;10-17.
15. Paykel E.S., Hollyman J.A., Freeling P., Sedgwick P. Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. J. Affect. Disord. 14(1):1988;83-95.
16. Philipp M., Delmo C.D., Buller R., Schwarze H., Winter P., Maier W., Benkert O. Differentiation between major and minor depression. Psychopharmacology - Berl. 106 Suppl:1992;S75-S78.
17. Philipp M. Is minor depression a valid diagnostic concept? Int. Clin. Psychopharmacol. 8(Suppl 1):1993;35-37.
18. Rosenberg R., Bech P., Mellergard M., Ottosson J.O. Secondary depression in panic disorder: an indicator of severity with a weak effect on outcome in alprazolam and imipramine treatment. Acta. Psychiatr. Scand (Suppl.). 365:1991;39-45.
19. Sherbourne C.D., Wells K.B., Hays R.D., Rogers W., Burnam M.A., Judd L.L. Subthreshold depression and depressive disorder: clinical characteristics of general medical and mental health specialty outpatients. Am. J. Psychiatry. 151(12):1994;1777-1784.
20. Skodol A.E., Schwartz S., Dohrenwend B.P., Levav I., Shrout P.E. Minor depression in a cohort of young adults in Israel. Arch. Gen. Psychiatry. 51(7):1994;542-551.
21. Tannock C., Katona C. Minor depression in the aged.Concepts, prevalence and optimal management. Drugs-Aging. 6(4):1995;278-292.
22. Winter P., Philipp M., Buller R., Delmo C.D., Schwarze H., Benkert O. Identification of minor affective disorders and implications for psychopharmacotherapy. J. Affect. Disord. 22:1991;125-133.